Oncocyte (NASDAQ:IMDX) Stock Dropped to Sell by Wall Street Zen

Wall Street Zen lowered shares of Oncocyte (NASDAQ:IMDX) from a hold rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other research analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a research note on Monday, September 21st. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Oncocyte in a research report on Tuesday, August 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oncocyte has a consensus rating of “Hold” and a consensus target price of $10.50.

Oncocyte Price Performance

NASDAQ:IMDX opened at $3.44 on Friday. The company has a market cap of $112.56 million, a P/E ratio of -2.31 and a beta of 1.80. The stock’s fifty day moving average price is $4.20 and its two-hundred day moving average price is $4.61. Oncocyte has a 1 year low of $2.42 and a 1 year high of $8.51.

Oncocyte (NASDAQ:IMDX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.24 million during the quarter.

Oncocyte Company Profile

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy.